| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Encephalomyelitis, Autoimmune, Experimental | 34 | 2021 | 45 | 9.390 |
Why?
|
| Th17 Cells | 16 | 2021 | 32 | 4.410 |
Why?
|
| Multiple Sclerosis | 17 | 2022 | 80 | 4.180 |
Why?
|
| Interferon-beta | 11 | 2021 | 40 | 3.460 |
Why?
|
| B-Lymphocytes | 9 | 2022 | 275 | 2.380 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 6 | 2022 | 19 | 1.960 |
Why?
|
| Interferon Type I | 4 | 2020 | 55 | 1.620 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2019 | 34 | 1.540 |
Why?
|
| Interleukin-17 | 14 | 2021 | 51 | 1.530 |
Why?
|
| Th1 Cells | 11 | 2016 | 35 | 1.420 |
Why?
|
| Mice, Inbred C57BL | 26 | 2021 | 1468 | 1.290 |
Why?
|
| Mice | 41 | 2022 | 4389 | 1.280 |
Why?
|
| Animals | 47 | 2022 | 9918 | 1.200 |
Why?
|
| Neuromyelitis Optica | 2 | 2020 | 7 | 1.120 |
Why?
|
| Autoimmunity | 7 | 2021 | 152 | 1.060 |
Why?
|
| Autoimmune Diseases | 4 | 2013 | 162 | 0.920 |
Why?
|
| Central Nervous System | 3 | 2018 | 36 | 0.910 |
Why?
|
| Cell Differentiation | 6 | 2021 | 394 | 0.880 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 8 | 2021 | 14 | 0.840 |
Why?
|
| Interleukin-23 | 2 | 2021 | 8 | 0.810 |
Why?
|
| Pertussis Toxin | 1 | 2021 | 7 | 0.760 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2021 | 1 | 0.760 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 228 | 0.690 |
Why?
|
| CD5 Antigens | 4 | 2012 | 12 | 0.680 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2015 | 56 | 0.650 |
Why?
|
| Lymphoid Tissue | 1 | 2018 | 7 | 0.640 |
Why?
|
| Neurogenic Inflammation | 1 | 2018 | 2 | 0.620 |
Why?
|
| Choristoma | 1 | 2018 | 6 | 0.610 |
Why?
|
| Brain | 5 | 2015 | 693 | 0.610 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2015 | 30 | 0.610 |
Why?
|
| Cytokines | 6 | 2021 | 437 | 0.610 |
Why?
|
| Germinal Center | 1 | 2018 | 20 | 0.610 |
Why?
|
| T-Lymphocytes | 9 | 2017 | 272 | 0.570 |
Why?
|
| Humans | 30 | 2022 | 26741 | 0.560 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 1391 | 0.490 |
Why?
|
| Signal Transduction | 10 | 2020 | 1332 | 0.480 |
Why?
|
| Immunomodulation | 2 | 2013 | 19 | 0.460 |
Why?
|
| Inflammation | 9 | 2022 | 594 | 0.450 |
Why?
|
| Female | 24 | 2022 | 14402 | 0.430 |
Why?
|
| Pancreatic Elastase | 1 | 2012 | 8 | 0.410 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2012 | 12 | 0.400 |
Why?
|
| Glycine | 1 | 2012 | 31 | 0.390 |
Why?
|
| Casein Kinase II | 2 | 2012 | 17 | 0.390 |
Why?
|
| Sulfonamides | 1 | 2012 | 68 | 0.380 |
Why?
|
| Biomarkers | 4 | 2022 | 729 | 0.370 |
Why?
|
| Cell Movement | 4 | 2021 | 352 | 0.350 |
Why?
|
| Cells, Cultured | 9 | 2018 | 967 | 0.340 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 15 | 0.330 |
Why?
|
| Interferon-gamma | 6 | 2013 | 102 | 0.330 |
Why?
|
| Mice, Transgenic | 8 | 2019 | 487 | 0.330 |
Why?
|
| Adoptive Transfer | 4 | 2021 | 25 | 0.310 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2008 | 7 | 0.310 |
Why?
|
| Graft Rejection | 3 | 2011 | 33 | 0.280 |
Why?
|
| Optic Neuritis | 2 | 2016 | 11 | 0.280 |
Why?
|
| Peptide Fragments | 5 | 2017 | 196 | 0.270 |
Why?
|
| Peptides | 2 | 2019 | 279 | 0.250 |
Why?
|
| Spleen | 3 | 2016 | 109 | 0.240 |
Why?
|
| Myelin Sheath | 3 | 2016 | 25 | 0.230 |
Why?
|
| Mice, Knockout | 11 | 2016 | 779 | 0.230 |
Why?
|
| Chronic Disease | 3 | 2022 | 263 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 109 | 0.230 |
Why?
|
| Cell Proliferation | 7 | 2017 | 761 | 0.230 |
Why?
|
| Antibodies | 3 | 2021 | 124 | 0.230 |
Why?
|
| Heart Transplantation | 3 | 2011 | 42 | 0.210 |
Why?
|
| Interleukin-10 | 2 | 2015 | 66 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2022 | 133 | 0.200 |
Why?
|
| Models, Animal | 2 | 2021 | 128 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2011 | 99 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 44 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 77 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 19 | 0.200 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2022 | 48 | 0.190 |
Why?
|
| Interferons | 1 | 2022 | 68 | 0.190 |
Why?
|
| Male | 12 | 2020 | 12817 | 0.190 |
Why?
|
| Antigen Presentation | 1 | 2022 | 78 | 0.190 |
Why?
|
| Drug Synergism | 1 | 2021 | 100 | 0.190 |
Why?
|
| Recurrence | 1 | 2022 | 315 | 0.190 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2021 | 6 | 0.190 |
Why?
|
| B-Cell Activating Factor | 1 | 2021 | 31 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2020 | 190 | 0.180 |
Why?
|
| Immunologic Memory | 2 | 2019 | 58 | 0.180 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2020 | 11 | 0.180 |
Why?
|
| Proteomics | 2 | 2020 | 177 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 189 | 0.180 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 82 | 0.180 |
Why?
|
| Spinal Cord | 2 | 2021 | 202 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 152 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 69 | 0.170 |
Why?
|
| Retinal Ganglion Cells | 2 | 2016 | 26 | 0.170 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 19 | 0.170 |
Why?
|
| Visual Acuity | 2 | 2016 | 105 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 26 | 0.170 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2019 | 9 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 446 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 41 | 0.160 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 203 | 0.160 |
Why?
|
| Adult | 5 | 2020 | 7350 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2019 | 61 | 0.160 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chemokine CXCL13 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2015 | 698 | 0.150 |
Why?
|
| Lymphocyte Depletion | 2 | 2015 | 8 | 0.150 |
Why?
|
| Natural Killer T-Cells | 1 | 2019 | 54 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 437 | 0.150 |
Why?
|
| Fluoxetine | 1 | 2017 | 11 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2021 | 511 | 0.150 |
Why?
|
| Sphingosine | 2 | 2015 | 22 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 266 | 0.140 |
Why?
|
| Paralysis | 2 | 2016 | 9 | 0.140 |
Why?
|
| Lysophospholipids | 2 | 2015 | 48 | 0.140 |
Why?
|
| Antigens, CD | 2 | 2015 | 134 | 0.140 |
Why?
|
| Astrocytes | 2 | 2014 | 73 | 0.130 |
Why?
|
| Autoantigens | 2 | 2019 | 210 | 0.130 |
Why?
|
| Glycoproteins | 3 | 2012 | 118 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 5 | 2019 | 263 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 118 | 0.130 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2015 | 2 | 0.130 |
Why?
|
| CD11b Antigen | 3 | 2017 | 42 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 2 | 2013 | 62 | 0.130 |
Why?
|
| Middle Aged | 2 | 2020 | 6790 | 0.130 |
Why?
|
| Glatiramer Acetate | 1 | 2015 | 4 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2015 | 49 | 0.120 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 16 | 0.120 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2014 | 2 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 624 | 0.120 |
Why?
|
| Toxoplasma | 1 | 2014 | 29 | 0.110 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2013 | 8 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 140 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2011 | 9 | 0.110 |
Why?
|
| Dementia | 1 | 2015 | 87 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 22 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2013 | 288 | 0.110 |
Why?
|
| Clonal Anergy | 1 | 2012 | 11 | 0.100 |
Why?
|
| Encephalomyelitis | 1 | 2012 | 1 | 0.100 |
Why?
|
| CD47 Antigen | 1 | 2012 | 4 | 0.100 |
Why?
|
| Encephalitis | 1 | 2012 | 18 | 0.100 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2013 | 58 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 73 | 0.100 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2012 | 1 | 0.100 |
Why?
|
| Neurons | 1 | 2014 | 273 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 46 | 0.100 |
Why?
|
| Interleukin-16 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 48 | 0.100 |
Why?
|
| Myeloid Cells | 2 | 2010 | 27 | 0.100 |
Why?
|
| Microglia | 2 | 2011 | 49 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2014 | 239 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2015 | 463 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2012 | 64 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2013 | 142 | 0.100 |
Why?
|
| Interleukin-7 | 1 | 2011 | 10 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2015 | 278 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2011 | 22 | 0.100 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2010 | 1 | 0.090 |
Why?
|
| Narcolepsy | 1 | 2010 | 7 | 0.090 |
Why?
|
| PPAR delta | 1 | 2010 | 3 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 109 | 0.090 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2010 | 1 | 0.090 |
Why?
|
| Angiotensin II | 1 | 2010 | 54 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 22 | 0.090 |
Why?
|
| Exosomes | 1 | 2011 | 86 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2010 | 229 | 0.080 |
Why?
|
| Receptors, CCR6 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Chemokine CCL20 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 2009 | 6 | 0.080 |
Why?
|
| Protein Binding | 2 | 2012 | 631 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 213 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2017 | 74 | 0.080 |
Why?
|
| Lithium | 1 | 2008 | 8 | 0.080 |
Why?
|
| Macrophages | 3 | 2017 | 272 | 0.080 |
Why?
|
| Phagocytosis | 1 | 2008 | 78 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 2 | 2020 | 86 | 0.070 |
Why?
|
| Immunization | 2 | 2019 | 117 | 0.070 |
Why?
|
| Transcriptome | 2 | 2022 | 198 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2012 | 282 | 0.070 |
Why?
|
| Time Factors | 2 | 2013 | 1564 | 0.060 |
Why?
|
| Young Adult | 1 | 2012 | 2573 | 0.060 |
Why?
|
| Adolescent | 1 | 2012 | 2945 | 0.060 |
Why?
|
| Gene Expression | 2 | 2020 | 405 | 0.060 |
Why?
|
| Cell Division | 1 | 2004 | 153 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2004 | 53 | 0.060 |
Why?
|
| Ligands | 1 | 2004 | 168 | 0.060 |
Why?
|
| Apoptosis | 2 | 2017 | 736 | 0.050 |
Why?
|
| Chemokines | 2 | 2014 | 73 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2022 | 5 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 32 | 0.050 |
Why?
|
| Neuroglia | 1 | 2022 | 29 | 0.050 |
Why?
|
| Axons | 1 | 2022 | 24 | 0.050 |
Why?
|
| Interleukin-12 | 2 | 2013 | 17 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 11 | 0.050 |
Why?
|
| Endocytosis | 1 | 2002 | 81 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2013 | 2262 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 41 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 453 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 2 | 2012 | 31 | 0.050 |
Why?
|
| Smad2 Protein | 1 | 2020 | 16 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2002 | 244 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 82 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2019 | 65 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 46 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 74 | 0.040 |
Why?
|
| Galactosylceramides | 1 | 2019 | 31 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 438 | 0.040 |
Why?
|
| Epitopes | 1 | 2019 | 170 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2002 | 466 | 0.040 |
Why?
|
| Cell Communication | 1 | 2019 | 66 | 0.040 |
Why?
|
| Myelin Basic Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 2017 | 8 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 21 | 0.040 |
Why?
|
| fas Receptor | 1 | 2017 | 20 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 110 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2016 | 28 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 20 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2016 | 162 | 0.030 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Thymocytes | 1 | 2015 | 12 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2015 | 27 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 4 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 135 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 115 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 177 | 0.030 |
Why?
|
| Maze Learning | 1 | 2015 | 78 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 93 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2014 | 21 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2013 | 5 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 23 | 0.030 |
Why?
|
| Interferon beta-1b | 1 | 2013 | 1 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2013 | 10 | 0.030 |
Why?
|
| Receptors, OX40 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2013 | 6 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 6 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2013 | 9 | 0.030 |
Why?
|
| Immunoassay | 1 | 2013 | 35 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2013 | 22 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 59 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2013 | 54 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 88 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 148 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 40 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 150 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 108 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2013 | 47 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2012 | 14 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2012 | 18 | 0.030 |
Why?
|
| Foam Cells | 1 | 2012 | 8 | 0.030 |
Why?
|
| Interferon beta-1a | 1 | 2012 | 4 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 21 | 0.030 |
Why?
|
| Disease Resistance | 1 | 2012 | 18 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 290 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2013 | 308 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2012 | 8 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 557 | 0.030 |
Why?
|
| Monocytes | 1 | 2013 | 131 | 0.030 |
Why?
|
| Tunica Intima | 1 | 2011 | 9 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2012 | 262 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 12 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 196 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 187 | 0.020 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 450 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 113 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 90 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 392 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2010 | 10 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2012 | 132 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2010 | 7 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2010 | 8 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2010 | 17 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2010 | 11 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2010 | 22 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2010 | 29 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 231 | 0.020 |
Why?
|
| 4-Aminobutyrate Transaminase | 1 | 2010 | 1 | 0.020 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2010 | 3 | 0.020 |
Why?
|
| GABA Agents | 1 | 2010 | 4 | 0.020 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Receptors, GABA | 1 | 2010 | 5 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 30 | 0.020 |
Why?
|
| Myelin Proteins | 1 | 2010 | 13 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 73 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 50 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 61 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 58 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 22 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 55 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 347 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 74 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 857 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 236 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 151 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1254 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 322 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 244 | 0.020 |
Why?
|
| Myocardium | 1 | 2010 | 171 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 798 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 31 | 0.020 |
Why?
|
| African Americans | 1 | 2010 | 348 | 0.020 |
Why?
|
| Antigens | 1 | 2008 | 66 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 503 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 542 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 60 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 662 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 36 | 0.020 |
Why?
|
| Phagocytes | 1 | 2005 | 15 | 0.020 |
Why?
|
| Heterozygote | 1 | 2005 | 64 | 0.020 |
Why?
|
| Aged | 1 | 2015 | 5152 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2002 | 5 | 0.010 |
Why?
|
| Adaptor Protein Complex 2 | 1 | 2002 | 4 | 0.010 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2002 | 31 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 338 | 0.010 |
Why?
|